What is CareDx?
Founded in 1998 and headquartered in South San Francisco, CareDx operates at the intersection of biotechnology and digital health. The company specializes in the discovery, development, and commercialization of clinically differentiated solutions tailored for transplant patients and their caregivers. By providing comprehensive testing services and genomics-based insights, CareDx addresses critical gaps in the pre- and post-transplant patient journey. Its market position is defined by a unique integration of diagnostic products and digital healthcare platforms, which collectively improve clinical outcomes and streamline the management of complex transplant cases.
How much funding has CareDx raised?
CareDx has raised a total of $98.5M across 5 funding rounds:
Debt
$6M
Debt
$12.5M
Debt
$15M
Stock Offering
$40M
Debt
$25M
Debt (2010): $6M, investors not publicly disclosed
Debt (2011): $12.5M led by GE Capital Healthcare Financial Services
Debt (2012): $15M supported by Oxford Finance Corporation and Silicon Valley Bank
Stock Issuance/Offering (2014): $40M, investors not publicly disclosed
Debt (2017): $25M, investors not publicly disclosed
Key Investors in CareDx
GE Capital Healthcare Financial Services
GE Capital is a prominent financial institution providing specialized investment advisory and capital solutions tailored to the unique needs of the healthcare sector.
Oxford Finance Corporation
Oxford Finance is a specialty finance firm that delivers flexible, debt-based financial solutions specifically designed for life sciences and healthcare enterprises.
Silicon Valley Bank
Silicon Valley Bank is a premier financial partner for the innovation economy, offering a comprehensive suite of banking, asset management, and investment services to high-growth companies.
What's next for CareDx?
Looking ahead, CareDx is positioned to leverage its recent capital influx to accelerate the adoption of its precision medicine portfolio. The company's strategic roadmap likely involves expanding its digital health ecosystem and deepening its genomics research capabilities to maintain its competitive edge in the transplant diagnostics market. As the healthcare industry shifts toward more personalized, data-driven interventions, CareDx is well-equipped to scale its operations, potentially exploring new therapeutic areas or enhancing its existing diagnostic pipeline to meet the evolving needs of global healthcare providers and transplant centers.
See full CareDx company page
